Nektar Therapeutics NKTR Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -242%— | -253.7%— | —— | —— | —— | |
| Net margin | -284.2%-123pp | -297.1%-169pp | -204.5%-23.8pp | -172.9%+17.2pp | -160.8%+34.2pp | |
| EBITDA margin | -240.6%-96.9pp | -251.8%-135pp | -177.7%-19.5pp | -151%+17.7pp | -143.8%+30.7pp | |
| Free cash flow margin | -366.6%-162pp | -377.8%-198pp | -304.1%-113pp | -248.3%-60.1pp | -204.2%+5.6pp | |
| Returns | ||||||
| Return on equity | -53.6%+146pp | -217.9%-86.3pp | -191.1%-29.5pp | —— | -199.8%-104pp | |
| Return on assets | -31%+12.0pp | -56.2%-20.2pp | -42%+2.9pp | -47%-4.7pp | -43%-6.3pp | |
| Return on invested capital | -35.4%+39.8pp | -86%-23.8pp | -71%+0.8pp | -93.2%-26.6pp | -75.2%-18.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.2× | 0.2×-0.1× | 0.2×0.0× | 0.3×0.0× | 0.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 10.2×+7.0× | 5×+0.7× | 4.2×0.0× | 2.6×-2.5× | 3.2×-2.9× | |
| Quick ratio | 10.2×+7.0× | 5×+0.7× | 4.2×0.0× | 2.6×-2.3× | 3.2×-2.6× | |
| Cash ratio | 0.1×0.0× | 0.1×-0.1× | 0.2×+0.1× | 0.1×-0.1× | 0.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-7.2× | 1×-0.7× | 1.1×-1.1× | —— | 7.3×+6.4× | |
| Debt-to-assets | 0.1×-0.3× | 0.3×0.0× | 0.3×0.0× | 0.5×+0.1× | 0.4×+0.1× | |
| Per Share | ||||||
| Book value per share | $23.29+2,285% | $5.32+20.2% | $4.49+28.2% | -$1.72-130% | $0.98+50.2% | |
| Valuation | ||||||
| Market capitalization | $2.06B+1,531% | $860.04M+401% | $1.08B+299% | $303.35M+25.6% | $126.55M-29.1% | |
| Enterprise value | $2.14B+874% | $942.6M+257% | $1.16B+211% | $393.17M+14.6% | $219.76M-23.5% | |
| Price / sales | 37.1×+35.7× | 15.6×+13.8× | 17.3×+14.4× | 4×+1.5× | 1.5×-0.5× | |
| Price / book | 3.6×-5.6× | 9.6×+6.7× | 12.7×+7.2× | —— | 9.2×+7.8× | |
| EV / sales | 38.5×+36.0× | 17.1×+14.4× | 18.6×+14.6× | 5.2×+1.6× | 2.5×-0.7× | |
| Free cash flow yield | -9.9%+131pp | -24.3%+79.0pp | -17.6%+47.9pp | -61.3%+11.3pp | -140.8%-34.8pp | |
| Earnings yield | -7.7%+103pp | -19.1%+54.5pp | -11.8%+50.2pp | -42.7%+30.6pp | -110.9%-12.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nektar Therapeutics's profit margins?
- Nektar Therapeutics (NKTR) runs a 100.0% gross margin and a -242.0% operating margin, with a -284.2% net margin.
- Where do Nektar Therapeutics's ratios come from?
- Every ratio is computed from Nektar Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
